Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival
辅助性利博西尼联合非甾体类芳香化酶抑制剂治疗HR阳性/HER2阴性早期乳腺癌患者:NATALEE研究疗效结果的5年随访及更新的总生存期
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105858
Crown, J; Stroyakovskii, D; Yardley, D A; Huang, C-S; Fasching, P A; Bardia, A; Chia, S; Im, S-A; Martin, M; Xu, B; Barrios, C H; Untch, M; Moroose, R; Hurvitz, S A; Hortobagyi, G N; Slamon, D J; Visco, F; Spera, G; Zarate, J P; Halligan, D; Li, Z; Loi, S